Printer Friendly

OrthoLogic Announces Publication of Preclinical Data on Fracture Repair; Data Offers Further Insight into Chrysalin's Mechanism of Action; Provides Additional Proof-of-Concept Support for Additional Indications.

TEMPE, Ariz. -- OrthoLogic Corp. (Nasdaq:OLGC), today announced the publication of a key preclinical study in support of the ongoing Chrysalin (TP508) fracture repair program.

This preclinical study, published in the current volume of Journal of Orthopaedic Research, the official publication of the Orthopedic Research Society, was conducted as collaboration among researchers led by Dr. Joseph Lane of the Hospital for Special Surgery in New York, Dr. Xinmin Li of the University of Chicago and Dr. James Ryaby, chief scientific officer of OrthoLogic.

This study tested the hypothesis whether Chrysalin injected into an experimental fracture would upregulate genes that control the inflammatory phase of fracture repair, and whether this would result in an earlier appearance of new vasculature into the fracture callus. Specifically, this study used Affymetrix genomescale profiling to link early gene expression changes to fracture histology and bone strength changes.

The first stage of this study showed that treatment of fractures with Chrysalin accelerated fracture repair as demonstrated by mechanical testing analysis, which measures the strength of the healing fracture. The second stage used blinded histological analysis to quantify the amount of new blood vessels in the healing fracture callus. The results showed Chrysalin-treated fracture callus had a significant increase in blood vessels relative to the controls. The final stage of this study used genome array analysis to assess changes in specific gene expression upon Chrysalin treatment. This gene array analysis showed that Chrysalin induced expression of inflammatory response modifiers and angiogenesis-related genes.

The study's conclusion states: "Chrysalin promotes fracture repair through a mechanism that involves an increased induction of a number of growth factors, enhanced expression of inflammatory mediators and angiogenesis-related genes."

"We believe studies such as these are critical for developing peptide-based therapeutics such as Chrysalin, and follow-up studies are underway to expand upon these results," said Dr. Ryaby. "These studies will be used to educate physicians on the mechanism of action of Chrysalin and provide additional evidence of Chrysalin's mechanism of action for other indications in orthopedic, dermal and cardiovascular tissue repair."

About Chrysalin(R)

Chrysalin (TP508) is a 23-amino acid peptide that represents the receptor-binding domain of the human thrombin molecule, the naturally occurring agent responsible for blood clotting and initiating many of the cellular events responsible for repair in both soft tissue and bone.

All cells contain high-affinity thrombin receptors, which led to the hypothesis that thrombin did more than form blood clots after wounding. It was discovered that thrombin acted as a signaling molecule to initiate the early stages of tissue repair. The basis for the development of Chrysalin started in 1985, when a class of synthetic peptides was developed representing a specific receptor-binding domain of thrombin that activates specific wound-healing signals.

Drugs based on the Chrysalin peptide can be used to mimic part of the thrombin response without stimulating the events associated with blood clotting and therefore have the potential to accelerate the natural cascade of healing events.

About OrthoLogic Corp.

OrthoLogic is a drug-development company focused on commercializing several potential therapeutics comprising the Chrysalin(R) Product Platform, a series of product candidates aimed at treating traumatic and chronic orthopedic indications in bone and soft tissue as well as cardiovascular repair and wound healing. All of these potential products are based on the Chrysalin synthetic peptide, also known as TP508.

OrthoLogic owns an exclusive license for all worldwide medical indications for the peptide, and is actively pursuing five orthopedic indications for Chrysalin. These include fracture repair and spine fusion, which are in human clinical trials, and cartilage defect repair, which is in late-stage preclinical trials. Ligament and tendon repair indications are in the preclinical studies stage. In non-orthopedic areas, a human clinical trial for chronic diabetic ulcers has been completed. OrthoLogic's product development pipeline also includes Chrysalin-based product candidates for dental bone formation and myocardial revascularization.

For more information, please visit the company's Web site: www.orthologic.com.

Statements in this press release or otherwise attributable to OrthoLogic regarding our business that are not historical facts are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which include the timing and acceptability of FDA filings and the efficacy and marketability of potential products, involve risks and uncertainties that could cause actual results to differ materially from predicted results. These risks include: delays in obtaining or inability to obtain FDA, institutional review board or other regulatory approvals of preclinical or clinical testing; unfavorable outcomes in our preclinical and clinical testing; the development by others of competing technologies and therapeutics that may have greater efficacy or lower cost; delays in obtaining or inability to obtain FDA or other necessary regulatory approval of our products; our inability to successfully and cost effectively develop or outsource manufacturing and marketing of any products we are able to bring to market; changes in FDA or other regulations that affect our ability to obtain regulatory approval of our products, increase our manufacturing costs or limit our ability to market our products; our possible need for additional capital in the future to fund the continued development of our Chrysalin Product Platform; and other factors discussed in our Form 10-K for the fiscal year ended December 31, 2004 our Form 10-Q for the quarter ended March 30, 2005, and other documents we file with the Securities and Exchange Commission.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 16, 2005
Words:889
Previous Article:Study: U.S. Online Giving Surpasses $3 Billion in 2004; Kintera/Luth Nonprofit Trend Report Shows More Than 8.6 million U.S. Households Gave Online...
Next Article:Arrowhead Completes Warrant Redemption; Receives over $20 Million in Net Proceeds.


Related Articles
OrthoLogic Reports First Quarter 2004 Results.
Proof of concept studies/translational research; new hypotheses: (a personal take on Panel 2. Discussion leader: Kimberly Struble).
OrthoLogic Reports Third Quarter 2004 Results.
OrthoLogic to Present at Second Annual Gabelli & Company Small-Cap Orthopedic Conference.
OrthoLogic Names Pharmaceutical Industry Veteran Dr. James M. Pusey President and CEO.
OrthoLogic to Present at B. Riley Annual Investor Conference.
OrthoLogic Reports First Quarter 2005 Results; Company Announces Completion of Patient Enrollment for Pivotal Phase 3 Trial of Chrysalin for...
AASTROM BIOSCIENCES REPORTS POSITIVE HUMAN JAW BONE RESULTS.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters